Caitlin Parmer-Chow

Caitlin Parmer-Chow

Auto-generated profile, based on publicly available information

Caitlin Parmer-Chow

Affiliation Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2026 in POCUS Journal
Verified
Journal Article
Open access
EBEvan Baum
Evan Baum
JKJohn Kugler
John Kugler
MLMichelle Lo
Michelle Lo
CPCaitlin Parmer-Chow
Caitlin Parmer-Chow
VNVishnu Nair
Vishnu Nair
AKAndre Kumar
Andre Kumar
Background: Artificial intelligence (AI) may improve ultrasound image acquisition and interpretation, but there have been few validation studies comparing AI-enabled machines to traditional measurement workflows. In this diagnostic comparison study, we evaluated AI-enabled point of care ultrasound (POCUS) compared to standard transthoracic echocardiography (TTE) measurements. Methods: Hospitalized adults at a single academic center who underwent both AI POCUS and standard TTE scans within 7 days of one another were eligible for inclusion. The AI POCUS software used convolutional neural network models to estimate left ventricular ejection fraction (LVEF), right ventricular fractional area change (RVFAC), valvular regurgitation, valvular stenosis, and inferior vena cava (IVC) diameter based on standard cardiac views. Agreement between AI POCUS and TTE was assessed using weighted Cohen’s κ and exploratory Bland-Altman analyses. Results: Seventy patients were included, with a median of 1 day (IQR 1–2 days, range 0–6 days) between AI POCUS and TTE examinations. AI POCUS demonstrated substantial agreement with TTE for LVEF (κ = 0.75, 95% CI 0.42–0.92). Agreement was lower for RVFAC (κ = -0.003), IVC diameter (κ = 0.382), aortic regurgitation (κ = 0.541), mitral regurgitation (κ = 0.438), tricuspid regurgitation (κ = 0.400), and aortic stenosis (κ = 0.086). Using a dichotomized threshold of LVEF <50% versus ≥50%, AI POCUS demonstrated 80.0% sensitivity and 88.6% specificity for detecting reduced LVEF. Conclusions: AI POCUS demonstrated substantial agreement with TTE for the estimation of LVEF. Agreement was lower for other echocardiographic parameters. These findings support the potential of AI POCUS for assessing left ventricular function.

9 September 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBShreya Battu
Shreya Battu
AMAndrew R. Moore
Andrew R. Moore
KLKatie Lebold
Katie Lebold
APAna Pacheco-Navarro
Ana Pacheco-Navarro
SPShaun Pienkos
Shaun Pienkos
ARAngela J. Rogers
Angela J. Rogers
Rationale: The impact of immunocompromising conditions on outcomes in critically ill patients with COVID-19 remains poorly characterized. We hypothesized that disparities in COVID-19 outcomes in immunocompromised patients may differ by viral strain and time course of the pandemic. Methods: We retrospectively reviewed SARS-CoV-2 RT-PCR positive patients admitted to intensive care (ICU) at Stanford from March 2020 to July 2022 using electronic medical records. Immunocompromised status included solid organ transplant; hematologic malignancy/transplant; solid cancer with metastases and recent chemotherapy; HIV/AIDS; and connective tissue disease on immunosuppression. SARS-CoV-2 strain periods were classified as pre-Delta (3/2020–8/2021), Delta (9/2021-12/2021), and Omicron (1/2022–7/2022). We assessed 90-day survival differences between immunocompromised and non-immunocompromised patients by strain using Cox-proportional hazards, adjusted for age, sex, and APACHE II score. Results: A total of 791 patients were included, 450 from the pre-Delta period, 114 from the Delta period, and 227 from the Omicron period. We compared 633 non-immunocompromised patients with 158 immunocompromised patients (77 during the pre-Delta, 22 Delta, and 59 Omicron periods). Patients admitted during the Omicron period were more likely to be immunocompromised (26%) compared to pre-Delta (17%) or Delta periods (19%; p = 0.008). Immunocompromise was associated with worse outcomes in the entire cohort after adjustment (HR 1.68, 95% CI 1.2–2.3, p < 0.001). However, when stratified by strain period, immunocompromised status was only significantly associated with higher 90-day mortality in patients from the Omicron period (42% vs 17%, HR 2.9, CI% 1.7–5.0, p < 0.001). Differences in mortality between immunocompromised and immunocompetent patients were not statistically different in either the pre-Delta (34% vs. 23%, HR 1.4, 95% CI 0.9–2.1, p = 0.15) or Delta periods (32% vs. 28% HR 1.0, 95% CI 0.4–2.5, p = 0.92). Notably, survival was significantly improved during the Omicron period compared to earlier strain periods in immunocompetent patients (HR 0.6, 95% CI 0.4–0.9, p = 0.02) but not for immunocompromised patients (HR 1.4, 95% CI 0.80–2.44, p = 0.24). Conclusion: In this retrospective cohort analysis of patients admitted to the ICU due to SARS-CoV-2 infection, we found that lower survival among immunocompromised patients was due to higher mortality during the Omicron period, with similar mortality between immunocompetent and immunocompromised patients during other periods.